Pinned Tweet
Advisors Edge
The leading outsourced equity research firm for Wealth Managers, RIAs, Family Offices, and sophisticated DIY investors.🧠 20+ years of portfolio management
📈 5x the S&P 500 over 17 years
💰 We invest our own capital alongside our researchNo hype. No recycled ideas. No “10 picks a month.”What we deliver:
⚙️ AI-powered research
🐺 Pack-driven insights from a 20-year insider network
🎯 High-conviction, alpha-focused ideasWe specialize in:
• Growth & value dislocations
• Microcaps & special situations
• SPACs & underfollowed opportunities🔍 Institutional-quality research
🧠 Independent thinking
📉 Adapt fast when facts changeThis is how modern investors source edge.
Welcome to Advisors Edge.
579
Was Kopernik Funds sleeping on $SA? Major legal risk that they apparently didn't analyze? Dave Iben is one of the best in the business...we track his fund as part of our "Smart Money Process"...$SA was his #1 position and he just added to it? 12+ Million shares...
What happened?
Still a big fan...nobody bats 1.000 in this game...
64
George, this reminds me of my days at Bear Stearns...Charlie Munger..."Show me the compensation system and I'll show you the results..."
Gavin gets paid big money if he hits the risk peddle and produces big returns...if he blows up, he blames it on the market and still has cashed out in the past..." I actually managed some personal money for hedge fund managers in the past....their instructions...just buy me Treasuries...
39
Check out my latest article: Why Buying Individual Stocks in the Coming Years Will Produce Big Winners linkedin.com/pulse/why-buyin… via @LinkedIn
26
advisorsedge.substack.com
PACK DISPATCH | OCTOBER 20, 2026 | THIRTY YEARS ON THE HUNT
I’ve been doing this for thirty years. I watched the dot-com crowd buy anything with “.com” in 2000. I watched the housing machine eat itself in 2008. I watched SPACs and crypto pull in the herd in 2021.
Every cycle, the easy trade looks permanent right before it ends. Today’s easy trade is passive investing: buy the index fund, automate the 401(k), never look. It worked for fifteen years. Here is my read: the forces behind it are reversing all at once.
1. THE EASY MONEY IN PASSIVE HAS BEEN MADE
An index fund (a fund that simply buys every stock in an index) needs a steady stream of buyers. For two decades that buyer was the Baby Boomer. In their peak earning years, Boomers poured record money into target-date funds, the set-and-forget 401(k) option, according to Boston College’s retirement center. By 2019, index funds passed active funds in U.S. stock-fund assets for the first time.
Now that buyer is retiring. More than 4.1 million Americans turn 65 every year through 2027 — over 11,200 a day, per the “Peak 65” research. Retirees don’t add to stock funds. They withdraw, and they move toward income: bonds, dividends, annuities. The biggest automatic buyer in history is turning into a seller.
2. INDEX FUNDS DON’T DO VALUATION. THEY DO FORMULAS.
Most ETFs are “cap-weighted”: the bigger a company’s stock market value, the more of it the fund must buy. Nobody asks what the business is worth. The money goes in by formula. That is momentum, and momentum cuts both ways.
Watch how the rules bend. In 2026 Nasdaq created a “Fast Entry” rule so giant IPOs (initial public offerings, a company’s first sale of stock to the public) can join the Nasdaq-100 after just 15 trading days instead of about three months. It also dropped its 10% minimum-float rule. SpaceX listed June 12 and entered the index July 7. Every fund tracking it had to buy. Ask the wolf’s question: who is selling this to me, and why now?
Even Warren Buffett got surprised by the flows. Berkshire bought most of its Apple between 2016 and 2018 at roughly 10 to 15 times earnings, per The Motley Fool. In 2024, near 30 times earnings, he sold about two-thirds of the stake around $180 to $230. Apple kept running and closed at $341 on October 13 at roughly 39 times trailing earnings. Buffett was right on value. He underestimated how far price-blind buying can stretch a stock.
When the buying is automatic, the price stops telling you what the business is worth. That is where wolves eat.
3. YOUR “DIVERSIFIED” INDEX IS ONE BIG AI BET
The S&P 500 is sold as safety in numbers. Tech alone is roughly a third of it, versus about 15% in the equal-weight version (ticker RSP, which gives all 500 stocks the same weight), per 24/7 Wall St.. Goldman Sachs puts AI-linked stocks at about 45% of the index. The broadest count, from BestBrokers, says 62%.
From May 2024 to June 2026 the index gained 142%. Strip out AI stocks and it gained 16%, per one analysis. That isn’t diversification. It’s a crowded trade with a ticker. I saw the same movie with telecom in 2000.
4. THE TAILWINDS ARE TURNING INTO HEADWINDS
Four things built this large-cap bull market. All four are fading or flipping.
RATES. Near zero for a decade. Now the 10-year Treasury sits around 5.2%, a 24-year high, and the Fed raised rates in September.
INFLATION. Tame for years. CPI hit 3.4% in August, up from 2.4% in February.
401(K) FLOWS. Boomers were accumulating. Now they are drawing down.
BUYBACKS. Companies buying back their own stock hit a record pace in 2026, an estimated $1.55 trillion. At 5% rates, that money gets expensive to borrow.
The result: the S&P 500’s Shiller CAPE (price versus ten years of average earnings) sits near 41, per YCharts. Its earnings yield of about 5% now pays you nothing extra over a risk-free Treasury. Why own the risk?
5. WHERE THE BIG WINNERS WILL COME FROM
Small caps started 2026 at about 18 times forward earnings versus 26-plus for the S&P 500, per The Motley Fool. The last time the gap was this wide was 1999. Small caps then beat large caps for more than a decade. The Russell 2000 just had its best first half in 35 years.
But don’t buy the small-cap index blind. Roughly 40% of the Russell 2000 is unprofitable. The index buys the junk with the gems. That is why stock picking is back. And here is your edge: a $100 billion fund can’t build a real position in a $500 million company. You can.
THE PACK PLAYBOOK
1. KNOW WHAT YOU OWN. Look up your index fund’s top ten holdings. If half your money rides on one theme, decide if that’s a choice or an accident.
2. CHECK THE PRICE TAG. Before you buy, compare a stock’s price-to-earnings ratio with its history and its peers. Flows don’t care. You must.
3. HUNT SMALLER. Look at profitable small and mid caps with real cash flow and low debt. That is where the mispricings live now.
4. FOLLOW THE INSIDERS. Executives buying their own stock with their own money is a signal. Track it.
5. ASK THE WOLF’S QUESTION. Every time: who is selling this to me, and why now?
The herd will stay on autopilot. The pack will do the work.
GOD BLESS THE WOLVES.
God Help The Rest.
Wolfpack Stocks publishes opinion and commentary for informational purposes only. Nothing here is individualized investment advice.
🤖 Made with AI
1
267
The Elites have corrupted the Financial Markets...and I’m pissed off...
advisorsedge.substack.com/p/…
🤖 Made with AI
17
Christmas Comes 4 Times a Year...
And almost nobody bothers too open the presents...
The process we developed for over 20 years at the Big Banks to produce 5X the S&P500...
advisorsedge.substack.com/p/…
🤖 Made with AI
51
Fred, totally agree...and been saying this for a while..and look at Kalshi and Polymarket...they are now introducing stock perpetuals...and gold perpetuals with significant (15X) leverage....who are the early, the private investors in these platforms...Kalshi...Henry Kravis, etc...Elites...Who is the founder? A former quant trader from Goldman, big surprise, not...and a President whose family is raping the country in crypto...oh, forgot, a non-existent SEC...
I'm convinced that gambling and speculation is a dopamine induced drug the same as heroin and alcohol. Also, with inflation, the millennials are out trying to make 100 to 1 returns in crypto, speculative trading, options, prediction markets...today's version of lottery tickets...
Our young people...I have 2 sons...they don.t gamble...are being looted by brain chemistry by the Elites...
Send lawyers, guns, and money, Dad, the shit Will hit the fan, someday...
This ends very badly...need to buy more Gold...$AEM , $GDXJ, , $PPTA
WSJ: "More than 100 proposed ETFs are tied to the real-time success of National Hockey League teams over the course of a season—including 32 that would double the daily change in a composite statistical measure of a team’s performance."
ETFs that enable one to bet on election results, "prediction markets" (Kalshi, Polymarket), "tokenized" stocks, non-stop betting ads during televised sporting events (FanDuel, DraftKings), 0DTE options, triple-levered ETFs and we have two casinos in little Nashua, NH (my hometown, population 85K).
The gambling culture in the U.S. is out of control and it's not a sign of a healthy society.
wsj.com/tech/ai/etfs-are-get…
96
Advisors Edge Research...25 years in the making...the best 13F analysis coming soon...our proprietary process led us to big winner, $LQDA...originally developed by our team at JPMorgan...we commit personal capital...
advisorsedgeresearch.substac…
🤖 Made with AI
102
What about the shareholders that were diluted? They got cash, but we lost a percentage of the company...also 2 years...tell that to Sanofi whose Dupixent comes up in 2031...sorry, your argument is flawed..
$NKTR lly did nothing wrong and HELPED nektar.
losing 2 years under patent? immaterial. slower launch? immaterial. 1.5b capex lly should have covered? immaterial. wacc? whack. immaterial.
nektar owns 100% of the drug and therefore they were not damaged. 100% >> 20% .
1
150
This is the problem with X.com...we get that you don.t like $NKTR...but to litter the site with your constant tweets is childish...I've always said, if we want to get rid of rubbish...make every poster put up their real names....no user names...
$NKTR. Closed at the low of the day per the norm. Let me know when this piece of shit ever closes at the high of the day. Such a shitty stock. I felt good until I read trial transcripts. Now I feel like shit. Howard is not good at running NKTR.
104
nice find...yes, he.s top tier...
Dr. Gregory St. John is stepping in as Vice President and Head of Medical Affairs, bringing 25+ years of immunology and dermatology experience.
Background & Pedigree
AbbVie Dermatology Leadership: St. John served as Therapeutic Area Lead / Head of Dermatology and Psoriatic Diseases in US Medical Affairs at AbbVie. AbbVie is widely regarded as the undisputed gold standard in immunology commercialization and medical strategy.
Blockbuster Launches: He directly steered medical strategy and evidence generation for Skyrizi (risankizumab) and Rinvoq (upadacitinib)—two of the most successful immunology franchise launches in pharmaceutical history.
Prior Big Biotech Roles: Prior to AbbVie, he spent years in medical affairs at Regeneron Pharmaceuticals, contributing to late-stage development and commercial alignment for major biologics like Kevzara (sarilumab).
Academic Foundation: Ph.D. in immunology/microbiology from Weill Cornell Medicine (trained in Carl Nathan’s lab).
Is He "Elite" for NKTR?
Yes—for this specific operational function, he is near the top tier.
Exact Indication Alignment: Nektar’s lead asset, rezpegaldesleukin (REZPEG / NKTR-358), is currently advancing through mid-to-late-stage trials in atopic dermatitis (AD) and alopecia areata (AA). Skyrizi and Rinvoq dominate these exact clinical ecosystems. St. John already has deep, pre-existing relationships with top key opinion leaders (KOLs), clinical trial investigators, and dermatology advocacy groups.
Medical Affairs is the Pre-Launch Engine: In late Phase 2 / Phase 3 biotech, Medical Affairs is not an administrative back-office job. It is responsible for Phase 3b/4 investigator-initiated trials, real-world evidence (RWE), advisory boards, and educating the specialist community ahead of commercial launch. AbbVie wrote the modern playbook on pre-launch disease-state education.
Validation of REZPEG’s Science: Elite commercial-stage executives with decades of large-cap pharma options (AbbVie, Regeneron) rarely jump to mid-cap turnaround biotechs unless they have inspected the Phase 2 mechanistic data and see clear potential for a differentiated, multi-billion-dollar therapeutic class (in this case, Treg induction vs. broad immunosuppression).
1
3
361
Just dropped...Why the Passive Investment Party Is Over...and why you need to be able to pick individual stocks in the future...
advisorsedge.substack.com/p/…
46
Because no Big Pharma is going to kick the tires until the $LLY situation is resolved...the money actually is secondary...clearing out the litigation may get to a re-rating on the stock...Big Pharma is a club...nobody wants to get involved in each other's legal tangles..
Replying to @tejada444
Why do people keep saying there is a legal overhang for $NKTR? Their downside in this is legal fees. There's nothing about this case that would preclude a buyer from acquiring them. It would be viewed as free upside.
Can anyone explain how owning a possible lottery ticket is an overhang to acquirers? What am I missing? "Legal overhang" would require some massively adverse consequence to $NKTR at the end of this, which to my knowledge does not exist?
3
665












